UNITED STATES INTERNATIONAL TRADE COMMISSION
`
`Washington, D.C.
`
`In the Matter of
`
`CERTAIN STRONTIUM-RUBIDIUM
`RADIOISOTOPE INFUSION SYSTEMS,
`AND COMPONENTS THEREOF
`INCLUDING GENERATORS
`
`Investigation No. 337-TA-1110
`
`NOTICE OF COMMISSION DETERMINATION TO REVIEW IN PART A FINAL
`INITIAL DETERMINATION FINDING NO SECTION 337 VIOLATION
`
`AGENCY:
`
` U.S. International Trade Commission.
`
`ACTION:
`
`Notice.
`
`SUMMARY: Notice is hereby given that the U.S. International Trade Commission has
`determined to review in part a final initial determination (“FID”) of the presiding administrative
`law judge (“ALJ”) finding no violation of section 337 of the Tariff Act of 1930, as amended.
`
`FOR FURTHER INFORMATION CONTACT: Houda Morad, Office of the General
`Counsel, U.S. International Trade Commission, 500 E Street SW., Washington, DC 20436,
`telephone (202) 708-4716. Copies of non-confidential documents filed in connection with this
`investigation are or will be available for inspection during official business hours (8:45 a.m. to
`5:15 p.m.) in the Office of the Secretary, U.S. International Trade Commission, 500 E Street
`SW., Washington, D.C. 20436, telephone (202) 205-2000. General information concerning the
`Commission may also be obtained by accessing its Internet server at https://www.usitc.gov. The
`public record for this investigation may be viewed on the Commission’s electronic docket
`(EDIS) at https://edis.usitc.gov. Hearing-impaired persons are advised that information on this
`matter can be obtained by contacting the Commission’s TDD terminal on (202) 205-1810.
`
`SUPPLEMENTARY INFORMATION: The Commission instituted this investigation on
`May 1, 2018, based on a complaint, as amended, filed by Bracco Diagnostics Inc. of Monroe
`Township, New Jersey (“Complainant” or “Bracco”). See 83 FR 19112-13 (May 1, 2018). The
`complaint, as amended, alleges violations of section 337 of the Tariff Act of 1930, as amended
`(19 U.S.C. 1337) (“section 337”), based upon the importation into the United States, the sale for
`importation, and the sale within the United States after importation of certain strontium-rubidium
`radioisotope infusion systems, and components thereof including generators, by reason of
`infringement of U.S. Patent Nos. 9,814,826; 9,750,869; and 9,750,870 (collectively, “the
`asserted patents”). See id. The notice of investigation names Jubilant DraxImage Inc. of
`Kirkland, Québec, Canada; Jubilant Pharma Limited of Singapore; and Jubilant Life Sciences of
`Noida, Uttar Pradesh, India (collectively, “Respondents” or “Jubilant”) as respondents in this
`
`1
`
`Bracco Ex. 2018
`Jubilant v. Bracco
`IPR2019-01449
`
`

`

`investigation. See id. The Office of Unfair Import Investigations is also a party to this
`investigation. See id.
`
`
`On February 8, 2019, the ALJ issued an ID (Order No. 27) finding by summary
`determination that Jubilant’s RUBY Rubidium Elution System Version 3.0 directly infringes the
`asserted patents. See Order No. 27 (Feb. 8, 2019), unreviewed, Comm’n Notice (Mar. 8, 2019).
`In addition, the ALJ determined that Jubilant’s RUBY Rubidium Elution System Version 3.1 and
`the RUBY Rubidium Elution System Version 4 do not directly infringe the asserted patents. See
`id. The ID (Order No. 27) declined to reach indirect infringement on summary determination.
`See id.
`
`
`The ALJ conducted an evidentiary hearing on February 11-12 and 15-17, 2019, and on
`August 1, 2019, issued the FID finding no violation of section 337. Specifically, the FID finds
`that the domestic industry requirement is satisfied and that all the asserted claims are infringed
`but invalid as obvious over the prior art. In addition, the ALJ issued a Recommended
`Determination (“RD”) recommending, should the Commission find a section 337 violation, that
`the Commission issue a limited exclusion order (“LEO”) barring entry of articles that infringe
`the asserted claims. The RD does not recommend that the Commission issue a cease and desist
`order or impose a bond during the period of Presidential review. Furthermore, as directed by the
`Commission, the RD provides findings with respect to the public interest and recommends a
`determination that the public interest factors do not preclude entry of the proposed LEO.
`
`On August 14, 2019, both Bracco and the Commission’s Investigative Attorney (“IA”)
`filed petitions for review of the FID. Bracco petitions for review of the FID’s findings with
`respect to invalidity, while the IA petitions for review of the FID’s findings with respect to
`domestic industry. On August 22, 2019, the parties filed responses to the respective petitions.
`
`The Commission has determined to review the FID in part. Specifically, the Commission
`has determined to review the FID’s findings with respect to invalidity and domestic industry.
`The Commission has determined not to review the remainder of the FID. At this time, the
`Commission does not request any briefing from the parties.
`
`The authority for the Commission’s determination is contained in section 337 of the
`Tariff Act of 1930, as amended (19 U.S.C. 1337), and in part 210 of the Commission’s Rules of
`Practice and Procedure (19 CFR part 210).
`
`
`By order of the Commission.
`
`Issued: September 30, 2019
`
`
`Lisa R. Barton
`Secretary to the Commission
`
`2
`
`